Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Jul
01
Today In Oncology
Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests
Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes
Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma
Patterns of ICI Use and Survival Outcomes in Metastatic Colorectal Cancer
Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo